| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424459000 | Organic coatings | 56 |
| 20080199518 | Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution - The present invention relates to controlled-release beads comprising diquinoline-substituted piperazine-piperidine compounds, such as 5-fluoro-8-{4-[4-[(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl}quinoline, or pharmaceutically acceptable salts thereof; to multiple particulate formulations comprising such beads; to methods of preparing such beads; and to methods of treating 5-HT | 08-21-2008 |
| 20080305165 | SUSTAINED RELEASE ORAL FORMULATION AND PROCESS FOR THE PREPARATION THEREOF - Disclosed is a multiple unit type sustained release oral formulation comprising sustained release pellets formed from granules containing an active ingredient and a water-insoluble polymer, the granules being coated with a sustained release base material; and rapid release granules containing the active ingredient, and a method for preparing the same. | 12-11-2008 |
| 20100166856 | PHARMACEUTICAL COMPOSITION IN THE FORM OF COATED MICROSPHERES FOR THE MODIFIED RELEASE OF A MUSCLE RELAXANT AND AN NSAID - The invention relates to a modified release pharmaceutical composition in capsules with coated microspheres, combining two active ingredients with radically different plasma concentration times, namely a muscle relaxant (tizanidine) and a non-steroidal anti-inflammatory drug (meloxicam), and pharmaceutically acceptable excipients or vehicles; as well as a method for producing the composition and the use of said combination for the preparation of a drug having synergic therapeutic effect in the treatment of spasticity, disorders related to the skeletal muscle and/or muscular ailments, and moderate to severe pain in general. | 07-01-2010 |
| 20100183713 | GASTROINTESTINAL-SPECIFIC MULTIPLE DRUG RELEASE SYSTEM - The present invention provides compositions and methods for the multiple release of a drug in the gastrointestinal tract of a subject through the use of an oral multiple drug release system. The system provides site-specific release of the drug to both the small intestine and the colon in the form of multiple controlled doses for long-lasting efficacy, thereby reducing the drug dosing frequency. | 07-22-2010 |
| 20110256218 | CONTROLLED RELEASE COMPOSITIONS COMPRISING MECLIZINE OR RELATED PIPERAZINE DERIVATIVES - The present invention provides pharmaceutically acceptable compositions for once-daily dosing comprising a piperazine derivative of H | 10-20-2011 |
| 20130189356 | PELLET FORMULATION FOR THE TREATMENT OF THE INTESTINAL TRACT - An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof. | 07-25-2013 |
| 20140004189 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS MEMANTINE | 01-02-2014 |
| 20150140089 | NOVEL FORMULATIONS OF NITROFURANS INCLUDING NIFURTIMOX WITH ENHANCED ACTIVITY WITH LOWER TOXICITY - The present invention relates to a novel formulation of sustained-release Nifurtimox with enhanced activity while having low toxicity. The formulation can improve patient compliance by reducing the frequency of administering the drug. | 05-21-2015 |
| 20160030412 | COMPOSITIONS AND METHODS FOR TREATMENT IN PARKINSON'S DISEASE PATIENTS - The invention provides dosage forms and methods for treating Parkinson's Disease, symptoms resulting from Parkinson's Disease, side effects resulting from treatment of Parkinson's Disease with other pharmaceutical agents, and reducing the progress of Parkinson's Disease. In various embodiments, the dosage forms and methods utilize nicotine and/or salts thereof for once daily administration resulting in four pulsatile releases following administration. | 02-04-2016 |
| 424460000 | Containing proteins or derivatives thereof (e.g., gelatin, etc.) | 1 |
| 20130122086 | METHOD FOR TREATING CELIAC DISEASE - Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine. | 05-16-2013 |
| 424461000 | Containing polysaccharide (e.g., cellulose sugars, etc.) | 27 |
| 20080226711 | PHARMACEUTICAL COMPOSITIONS OF DULOXETINE - The present invention relates to solid oral pharmaceutical compositions of duloxetine, process for preparing such compositions and method of using such compositions. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core comprising duloxetine, optional separating coat and an enteric coat. | 09-18-2008 |
| 20080317845 | Duloxetine Formulation - A duloxetine pellet formulation comprises: (i) a core including a desired amount of duloxetine; (ii) an enteric coating comprising hydroxypropylmethylcellulose phthalate (HPMCP) as an enteric polymer; and, optionally, (iii) a separating layer located between the core and the enteric coating, the separating layer including polyvinyl alcohol and a low molecular weight hydroxypropylmethylcellulose (HPMC). | 12-25-2008 |
| 20080317846 | Pulsatile release histamine H2 antagonist dosage form - A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity/manifestation of gastric acid secretion (and/or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations. | 12-25-2008 |
| 20090053308 | Release-Control Composition - The present invention relates to a controlled release capsule preparation for oral administration, which contains (i) a granule containing a physiologically active substance which is a compound represented by the formula: | 02-26-2009 |
| 20090208570 | Extended Release Dosage forms of Metoprolol - The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms. | 08-20-2009 |
| 20090238869 | PROPRANOLOL FORMULATIONS - Controlled-release propranolol formulations comprise a core comprising a pharmaceutically acceptable propranolol salt and an inert core; and a coating disposed on the core, the coating comprising about 70:30 to about 85:15 of ethylcellulose:polyvinylpyrrolidone or about 60:40 to about 75:25 of ethylcellulose:hydroxypropylmethylcellulose. | 09-24-2009 |
| 20100086589 | EXTENDED RELEASE PELLET FORMULATION CONTAINING PRAMIPEXOLE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient. | 04-08-2010 |
| 20100221328 | SUSTAINED-RELEASE FORMULATIONS - Described herein are extended-release or sustained-release formulations suitable for highly soluble pharmacologically active compounds, for example, amantadine. Dosage units for providing extended release are provided by the present invention. In some embodiments, the dosage unit comprises a plurality of coated beads having drug layer and a coating layer, wherein the coating layer comprises an ethylcellulose polymer. In some embodiments, near zero-order release of the active compound is achieved. | 09-02-2010 |
| 20100272798 | CONTROLLED RELEASE PREPARATION - A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient. | 10-28-2010 |
| 20100278911 | CONTROLLED RELEASE PREPARATION - A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient. | 11-04-2010 |
| 20100285120 | CONTROLLED RELEASE PREPARATION - A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient. | 11-11-2010 |
| 20110189273 | AMANTADINE COMPOSITIONS AND METHODS OF USE - Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration. | 08-04-2011 |
| 20110287096 | MODIFIED GASTRORETENTIVE DRUG DELIVERY SYSTEM FOR AMINE DRUGS - Oral dosage forms for basic amine drugs, the dosage forms having a gastro-retentive component and a non gastro-retentive component. These dosage forms are capable of providing both IR and SR release rates for these drugs. In addition, they provide for release of the drug in the stomach and/or intestine of a mammal to which such dosage forms are administered. Such dosage forms include tablets and capsules. Such dosage forms provide improved bioavailability of otherwise poorly bioavailable basic amine drugs. | 11-24-2011 |
| 20130017259 | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients - The invention provides dosage forms and methods utilizing nicotine to treat symptoms of a neurologic disorder. In some embodiments, the invention provides compositions for treatment of gait and balance problems associated with Parkinson's Disease. | 01-17-2013 |
| 20140178468 | MULTIPARTICULATE EXTENDED-RELEASE COMPOSITION OF MESALAMINE - The present invention relates to a multiparticulate extended-release pharmaceutical composition of mesalamine comprising a) an inert core, b) an active ingredient layer and one or more pharmaceutically acceptable excipients, c) an inner coating layer comprising a water-insoluble cellulose derivative, and d) an outer coating layer comprising an enteric polymer. | 06-26-2014 |
| 20140242162 | PHARMACEUTICAL COMPOSITIONS COMPRISING 40 - O - ( 2 - HYDROXY) ETHYL - RAPAMYCIN - The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical formulations, to methods of preparing said pharmaceutical formulations and said dosage forms, to uses of said pharmaceutical formulations and said dosage for the manufacture of a medicament for the treatment or prevention of diseases or conditions responsive to inhibition of mTOR signaling pathway, such as for instance proliferative diseases or immunosuppression. | 08-28-2014 |
| 20140294950 | METHODS OF TREATING OBESITY IN RESPONDER AND NON-RESPONDER POPULATIONS - The disclosed embodiments relate to, dosing regimens for the administration of topiramate, optionally in combination with one or more sympathomimetic agents such as phentermine. The dosing regimens can, for example, limit the exposure of subjects to topiramate, identify subjects who are unlikely to obtain a benefit from treatment with escalating dosages of topiramate (with or without the sympathomimetic agent, such as phentermine), or both, thereby reducing or eliminating harmful or intolerable side effects in subjects who are unlikely to respond to treatment and maximizing the therapeutic benefits from treatment in subjects who do respond. | 10-02-2014 |
| 20150010626 | Escalating Dosing Regimen for Effecting Weight Loss and Treating Obesity - The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions. | 01-08-2015 |
| 20150056275 | CONTROLLED-RELEASE SOLID DOSAGE FORMS OF MESALAMINE - Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-release solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention relates to a method of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowel disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease. | 02-26-2015 |
| 20150086626 | STABLE DOSAGE FORMS OF SKELETAL MUSCLE RELAXANTS WITH EXTENDED RELEASE COATING - A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed along with a method of preparation therefor. The dosage form comprises active core particles which are individually surrounded by a water insoluble polymer coating which lacks plasticizer. | 03-26-2015 |
| 20150125521 | COMPOSITIONS FOR TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER - Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate. | 05-07-2015 |
| 20160022620 | ENCAPSULATED COMPOSITION FOR BINDING ALDEHYDES IN THE STOMACH - The present invention relates to non-toxic composition containing, as active compounds, one or more aldehyde-binding compounds, such as L- or D-cysteine, N-acetyl cysteine, and the pharmaceutically acceptable salts thereof, and optionally one or more further active compounds selected from sulphites and xylitol, the composition being used for decreasing the risk of a subject contracting cancer of the stomach, and indirectly of the small intestine and the large intestine. The composition is formulated into a controlled-release formulation consisting of granules contained in a capsule. | 01-28-2016 |
| 20160106683 | TIMED, PULSATILE RELEASE SYSTEMS - A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating. Each Timed Pulsatile Release (TPR) bead population exhibits pre-determined lag-time followed by differing release characteristics. The composition and thickness of the barrier coating, composition and thickness of the lag-time coating, ratio of IR beads to one or more TPR bead populations and total dose may be varied depending on the alkalinity, pH-dependent solubility and elimination half-life of the active ingredients to achieve target PK profiles (suitable for a once or twice daily dosing regimen) in patients in need of such medications. | 04-21-2016 |
| 20160128945 | CONTROLLED RELEASE PREPARATION - A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient. | 05-12-2016 |
| 20160136147 | EXTENDED RELEASE NICOTINAMIDE FORMULATION - The invention provides various extended release granules of nicotinamide. Granule properties can be enhanced by the inclusion of a conductive filler. | 05-19-2016 |
| 20160143864 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS OF METOPROLOL - The present invention relates to timed extended-release pharmaceutical compositions comprising metoprolol and an extended-release polymer. The pharmaceutical compositions of the present invention exhibit an in-vivo lag time of at least 2 hours as and a T | 05-26-2016 |
| 20190142786 | METHODS OF TREATING OBESITY IN RESPONDER AND NON-RESPONDER POPULATIONS | 05-16-2019 |
| 424462000 | Containing solid synthetic polymers | 19 |
| 20080226712 | Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles - The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions. | 09-18-2008 |
| 20090017113 | DULOXETINE FORMULATIONS - Duloxetine pellets having an enteric coating containing a polymethacrylate polymer can be formed with desirable release rates/profile and stability. | 01-15-2009 |
| 20090068260 | BETA-1-SELECTIVE ADRENOCEPTOR BLOCKING AGENT COMPOSITIONS AND METHODS FOR THEIR PREPARATION - The present invention provides extended release pharmaceutical compositions of a beta blocker such as, but not limited to, metoprolol succinate as the active ingredient, optionally also comprising a diuretic such as but not limited to hydrochlorothiazide, and methods of preparing such extended release pharmaceutical compositions. | 03-12-2009 |
| 20090175935 | PHARMACEUTICAL COMPOSITIONS OF DULOXETINE - The present invention relates to solid oral pharmaceutical compositions of duloxetine, process for preparing such compositions and method of using such compositions. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core comprising duloxetine, optional separating coat and an enteric coat, wherein the enteric coat comprises methacrylic acid copolymer. | 07-09-2009 |
| 20090220593 | EXTENDED RELEASE DOSAGE FORMS OF QUETIAPINE - The present invention relates to multiple unit extended release dosage forms of quetiapine for oral administration, wherein each unit comprises a core containing quetiapine and one or more of pharmaceutically acceptable excipients coated with a rate-controlling coating and process for the preparation thereof. | 09-03-2009 |
| 20090258066 | COMPOSITIONS COMPRISING WEAKLY BASIC DRUGS AND CONTROLLED-RELEASE DOSAGE FORMS - The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing a weakly basic drug core, a layer of alkaline buffer, and a controlled-release coating. The present invention is also directed to pharmaceutical dosage forms, including orally disintegrating tablets, conventional tablets, and capsules, and methods for their preparation. | 10-15-2009 |
| 20090263478 | CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF - Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions. | 10-22-2009 |
| 20100047342 | Method and Composition for Administering an NMDA Receptor Antagonist to a Subject - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject. | 02-25-2010 |
| 20100047343 | MULTIPARTICULATE FORMULATION HAVING TRAMADOL IN IMMEDIATE AND CONTROLLED RELEASE FORM - A multi-particulate pharmaceutical composition of rapid release particles and controlled release particles comprising tramadol or a salt thereof is provided. The composition provides a rapid and controlled release of tramadol or a salt thereof in a substantially pH independent manner after oral administration to a subject. The composition can be included in a capsule, caplet, sachet, or other solid dosage form adapted to retain and then release solid pharmaceutical compositions. | 02-25-2010 |
| 20110165234 | EXTENDED RELEASE VENLAFAXINE FORMULATION - A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet. | 07-07-2011 |
| 20110223247 | PHARMACEUTICAL COMPOSITIONS FOR RELEASE CONTROL OF METHYLPHENIDATE - Disclosed is a pharmaceutical composition for release control comprising a plurality of particles for release control. The plurality of particles for release control comprise a core material containing methylphenidate and a polymer coating layer for release control formed on the core material. The plurality of particles for release control are divided into two or more groups based on the average thickness of the polymer coating layer for release control. The particle groups are identical in terms of the composition of the polymer in the polymer coating layer, but are different in terms of the average thickness of the coated layer. The pharmaceutical composition for release control according to the present invention may control the release pattern of methylphenidate contained in the core material as desired, and can be used as an oral formulation in a variety of forms such as orally disintegrating tablets, etc. | 09-15-2011 |
| 20110287097 | PHARMACEUTICAL COMPOSITIONS COMPRISING ROPINIROLE - Controlled release pharmaceutical compositions comprising ropinirole or pharmaceutically acceptable salts thereof, wherein embodiments have ropinirole embedded in a matrix comprising one or more polymers, and the composition in monolithic form or in multiparticulate form. | 11-24-2011 |
| 20110311620 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS - The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors. | 12-22-2011 |
| 20130195974 | PH-DEPENDENT GRADUAL RELEASE PHARMACEUTICAL COMPOSITION - The invention concerns a pH-dependent gradual sustained release composition for increasing the pH in the upper part of the small intestines. Particles of the composition are provided with a multilayer polymer coating of specific structure which ensures the gradual release of the active agent in the range of pH 4.5 to 5.5. A process for preparing said composition is also claimed. | 08-01-2013 |
| 20130230587 | SUSTAINED RELEASE COMPOSITIONS - Sustained release compositions comprising plurality of sustained release beads are disclosed. Particularly the sustained release beads comprise coated drug-resin complexes comprising drug-resin complexes of at least one active agent and at least one ion-exchange resin; coated with at least one release modifier. | 09-05-2013 |
| 20140044781 | Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof - The present invention relates provides pharmaceutical compositions comprising an amorphous carvedilol salt and one or more pharmaceutically acceptable excipients, wherein the amorphous carvedilol salt is formed in situ during the preparation of the pharmaceutical composition. The amorphous carvedilol salt is preferably an amorphous carvedilol phosphate salt. The pharmaceutical compositions can be prepared by providing one or more inert cores; contacting the core or cores with a solution or a dispersion comprising carvedilol, an acid component and optionally a binder, in a solvent; removing the solvent; and optionally coating the core or cores with an extended release composition. Preferred pharmaceutical compositions contain both immediate-release pellets and at least one population of extended-release pellet. | 02-13-2014 |
| 20140287038 | Orally Effective Methylphenidate Extended Release Powder and Aqueous Suspension Product - An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile. | 09-25-2014 |
| 20140356425 | COMPOSITION AND METHOD FOR TREATING NEUROLOGICAL DISEASE - Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided. | 12-04-2014 |
| 20150366825 | MULTIPARTICULATE PHARMACEUTICAL COMPOSITION COMPRISING A MULTITUDE OF TWO KINDS OF PELLETS - Multiparticulate pharmaceutical composition comprising a multitude of two kinds of pellets, A and B, each comprising metoprolol or a pharmaceutically acceptable salt thereof as an active pharmaceutical ingredient, wherein the pellets A are coated with a coating layer comprising at least 30% by weight of a polymeric compound consisting of one or more (meth)acrylate copolymers polymerized from 20 to 40% by weight of ethyl acrylate, 60 to 80% by weight of methyl methacrylate and 0 or less than 5% by weight of methacrylic acid or acrylic acid, in an amount sufficient to result in an active pharmaceutical ingredient release profile according to USP in pH 6.8 test medium with a release rate of less than 20% after 4 hours, wherein the pellets B are not coated or coated with a coating layer and show an active pharmaceutical ingredient release profile according to USP in pH 6.8 test medium with an active pharmaceutical ingredient release rate of more than 40% after 4 hours, wherein the metoprolol release rate of the pellets A in pH 1.2 test medium according to USP with the addition of 40% (v/v) ethanol is •not more than 15% after 15 minutes •more than 15 up to 40% after 30 minutes, wherein the metoprolol release rate of the pellets B in pH 1.2 test medium according to USP with the addition of 40% (v/v) ethanol is •more than 15% after 15 minutes •more than 40% after 30 minutes and wherein the pellets A and B are present in the multiparticulate pharmaceutical composition in a relation resulting in a combined active pharmaceutical ingredient release profile of the multiparticulate pharmaceutical composition according to USP in pH 6.8 test medium with releases rates of •not more than 25% after 1 hour •20 to 40% after 4 hours •40 to 60% after 8 hours •not less than 80% after 20 hours. | 12-24-2015 |
